nodes	percent_of_prediction	percent_of_DWPC	metapath
Fenofibrate—CYP2C9—Teniposide—lymphatic system cancer	0.158	0.35	CbGbCtD
Fenofibrate—CYP3A4—Cytarabine—lymphatic system cancer	0.0934	0.207	CbGbCtD
Fenofibrate—CYP3A4—Teniposide—lymphatic system cancer	0.092	0.203	CbGbCtD
Fenofibrate—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0644	0.142	CbGbCtD
Fenofibrate—CYP3A4—Vincristine—lymphatic system cancer	0.0443	0.0979	CbGbCtD
Fenofibrate—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.0011	0.00201	CcSEcCtD
Fenofibrate—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.0011	0.00201	CcSEcCtD
Fenofibrate—Anaemia—Bleomycin—lymphatic system cancer	0.0011	0.002	CcSEcCtD
Fenofibrate—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00109	0.00199	CcSEcCtD
Fenofibrate—Asthenia—Teniposide—lymphatic system cancer	0.00108	0.00197	CcSEcCtD
Fenofibrate—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00107	0.00196	CcSEcCtD
Fenofibrate—Malaise—Bleomycin—lymphatic system cancer	0.00107	0.00196	CcSEcCtD
Fenofibrate—Pruritus—Teniposide—lymphatic system cancer	0.00106	0.00194	CcSEcCtD
Fenofibrate—Arrhythmia—Carmustine—lymphatic system cancer	0.00106	0.00194	CcSEcCtD
Fenofibrate—Leukopenia—Bleomycin—lymphatic system cancer	0.00106	0.00194	CcSEcCtD
Fenofibrate—Cystitis—Methotrexate—lymphatic system cancer	0.00106	0.00194	CcSEcCtD
Fenofibrate—Cardiac disorder—Vincristine—lymphatic system cancer	0.00106	0.00193	CcSEcCtD
Fenofibrate—Alopecia—Carmustine—lymphatic system cancer	0.00105	0.00192	CcSEcCtD
Fenofibrate—Body temperature increased—Fludarabine—lymphatic system cancer	0.00105	0.00191	CcSEcCtD
Fenofibrate—Mental disorder—Carmustine—lymphatic system cancer	0.00104	0.00191	CcSEcCtD
Fenofibrate—Malnutrition—Carmustine—lymphatic system cancer	0.00104	0.00189	CcSEcCtD
Fenofibrate—Erythema—Carmustine—lymphatic system cancer	0.00104	0.00189	CcSEcCtD
Fenofibrate—Cough—Bleomycin—lymphatic system cancer	0.00104	0.00189	CcSEcCtD
Fenofibrate—Angiopathy—Vincristine—lymphatic system cancer	0.00103	0.00188	CcSEcCtD
Fenofibrate—Diarrhoea—Teniposide—lymphatic system cancer	0.00103	0.00188	CcSEcCtD
Fenofibrate—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00102	0.00187	CcSEcCtD
Fenofibrate—Chest pain—Bleomycin—lymphatic system cancer	0.00101	0.00185	CcSEcCtD
Fenofibrate—Myalgia—Bleomycin—lymphatic system cancer	0.00101	0.00185	CcSEcCtD
Fenofibrate—Alopecia—Vincristine—lymphatic system cancer	0.001	0.00183	CcSEcCtD
Fenofibrate—Back pain—Carmustine—lymphatic system cancer	0.001	0.00183	CcSEcCtD
Fenofibrate—Discomfort—Bleomycin—lymphatic system cancer	0.000999	0.00182	CcSEcCtD
Fenofibrate—Mental disorder—Vincristine—lymphatic system cancer	0.000996	0.00182	CcSEcCtD
Fenofibrate—Ecchymosis—Methotrexate—lymphatic system cancer	0.000993	0.00181	CcSEcCtD
Fenofibrate—Bladder pain—Methotrexate—lymphatic system cancer	0.000993	0.00181	CcSEcCtD
Fenofibrate—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000989	0.00181	CcSEcCtD
Fenofibrate—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000983	0.00179	CcSEcCtD
Fenofibrate—Alopecia—Mitoxantrone—lymphatic system cancer	0.000978	0.00179	CcSEcCtD
Fenofibrate—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000974	0.00178	CcSEcCtD
Fenofibrate—Oedema—Bleomycin—lymphatic system cancer	0.000969	0.00177	CcSEcCtD
Fenofibrate—Erythema—Mitoxantrone—lymphatic system cancer	0.000964	0.00176	CcSEcCtD
Fenofibrate—Infection—Bleomycin—lymphatic system cancer	0.000963	0.00176	CcSEcCtD
Fenofibrate—Anaemia—Carmustine—lymphatic system cancer	0.000958	0.00175	CcSEcCtD
Fenofibrate—Back pain—Vincristine—lymphatic system cancer	0.000957	0.00175	CcSEcCtD
Fenofibrate—Vomiting—Teniposide—lymphatic system cancer	0.000956	0.00175	CcSEcCtD
Fenofibrate—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000949	0.00173	CcSEcCtD
Fenofibrate—Asthenia—Fludarabine—lymphatic system cancer	0.000949	0.00173	CcSEcCtD
Fenofibrate—Rash—Teniposide—lymphatic system cancer	0.000948	0.00173	CcSEcCtD
Fenofibrate—Dermatitis—Teniposide—lymphatic system cancer	0.000948	0.00173	CcSEcCtD
Fenofibrate—Headache—Teniposide—lymphatic system cancer	0.000942	0.00172	CcSEcCtD
Fenofibrate—Pruritus—Fludarabine—lymphatic system cancer	0.000935	0.00171	CcSEcCtD
Fenofibrate—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000935	0.00171	CcSEcCtD
Fenofibrate—Back pain—Mitoxantrone—lymphatic system cancer	0.000932	0.0017	CcSEcCtD
Fenofibrate—Leukopenia—Carmustine—lymphatic system cancer	0.000928	0.00169	CcSEcCtD
Fenofibrate—Anorexia—Bleomycin—lymphatic system cancer	0.000924	0.00169	CcSEcCtD
Fenofibrate—Anaemia—Vincristine—lymphatic system cancer	0.000915	0.00167	CcSEcCtD
Fenofibrate—Photosensitivity—Methotrexate—lymphatic system cancer	0.000908	0.00166	CcSEcCtD
Fenofibrate—Hypotension—Bleomycin—lymphatic system cancer	0.000906	0.00165	CcSEcCtD
Fenofibrate—Diarrhoea—Fludarabine—lymphatic system cancer	0.000905	0.00165	CcSEcCtD
Fenofibrate—Hypertension—Carmustine—lymphatic system cancer	0.000895	0.00163	CcSEcCtD
Fenofibrate—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000894	0.00163	CcSEcCtD
Fenofibrate—Nausea—Teniposide—lymphatic system cancer	0.000894	0.00163	CcSEcCtD
Fenofibrate—Anaemia—Mitoxantrone—lymphatic system cancer	0.000891	0.00163	CcSEcCtD
Fenofibrate—Vertigo—Vincristine—lymphatic system cancer	0.000889	0.00162	CcSEcCtD
Fenofibrate—Leukopenia—Vincristine—lymphatic system cancer	0.000886	0.00162	CcSEcCtD
Fenofibrate—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000883	0.00161	CcSEcCtD
Fenofibrate—Chest pain—Carmustine—lymphatic system cancer	0.000883	0.00161	CcSEcCtD
Fenofibrate—Myalgia—Carmustine—lymphatic system cancer	0.000883	0.00161	CcSEcCtD
Fenofibrate—Anxiety—Carmustine—lymphatic system cancer	0.00088	0.00161	CcSEcCtD
Fenofibrate—Paraesthesia—Bleomycin—lymphatic system cancer	0.00087	0.00159	CcSEcCtD
Fenofibrate—Malaise—Mitoxantrone—lymphatic system cancer	0.000869	0.00159	CcSEcCtD
Fenofibrate—Dyspnoea—Bleomycin—lymphatic system cancer	0.000864	0.00158	CcSEcCtD
Fenofibrate—Renal failure acute—Methotrexate—lymphatic system cancer	0.000864	0.00158	CcSEcCtD
Fenofibrate—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000863	0.00158	CcSEcCtD
Fenofibrate—Hypertension—Vincristine—lymphatic system cancer	0.000854	0.00156	CcSEcCtD
Fenofibrate—Oedema—Carmustine—lymphatic system cancer	0.000846	0.00155	CcSEcCtD
Fenofibrate—Decreased appetite—Bleomycin—lymphatic system cancer	0.000843	0.00154	CcSEcCtD
Fenofibrate—Myalgia—Vincristine—lymphatic system cancer	0.000843	0.00154	CcSEcCtD
Fenofibrate—Cough—Mitoxantrone—lymphatic system cancer	0.000841	0.00154	CcSEcCtD
Fenofibrate—Infection—Carmustine—lymphatic system cancer	0.000841	0.00154	CcSEcCtD
Fenofibrate—Vomiting—Fludarabine—lymphatic system cancer	0.000841	0.00154	CcSEcCtD
Fenofibrate—Rash—Fludarabine—lymphatic system cancer	0.000834	0.00152	CcSEcCtD
Fenofibrate—Dermatitis—Fludarabine—lymphatic system cancer	0.000833	0.00152	CcSEcCtD
Fenofibrate—Hypertension—Mitoxantrone—lymphatic system cancer	0.000832	0.00152	CcSEcCtD
Fenofibrate—Pain—Bleomycin—lymphatic system cancer	0.000829	0.00151	CcSEcCtD
Fenofibrate—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000828	0.00151	CcSEcCtD
Fenofibrate—Headache—Fludarabine—lymphatic system cancer	0.000828	0.00151	CcSEcCtD
Fenofibrate—Tachycardia—Carmustine—lymphatic system cancer	0.000826	0.00151	CcSEcCtD
Fenofibrate—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000821	0.0015	CcSEcCtD
Fenofibrate—Myalgia—Mitoxantrone—lymphatic system cancer	0.000821	0.0015	CcSEcCtD
Fenofibrate—Chest pain—Mitoxantrone—lymphatic system cancer	0.000821	0.0015	CcSEcCtD
Fenofibrate—Anxiety—Mitoxantrone—lymphatic system cancer	0.000818	0.00149	CcSEcCtD
Fenofibrate—Discomfort—Mitoxantrone—lymphatic system cancer	0.000811	0.00148	CcSEcCtD
Fenofibrate—Oedema—Vincristine—lymphatic system cancer	0.000808	0.00148	CcSEcCtD
Fenofibrate—Anorexia—Carmustine—lymphatic system cancer	0.000807	0.00147	CcSEcCtD
Fenofibrate—Infection—Vincristine—lymphatic system cancer	0.000802	0.00147	CcSEcCtD
Fenofibrate—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000799	0.00146	CcSEcCtD
Fenofibrate—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000797	0.00146	CcSEcCtD
Fenofibrate—Nervous system disorder—Vincristine—lymphatic system cancer	0.000792	0.00145	CcSEcCtD
Fenofibrate—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000791	0.00144	CcSEcCtD
Fenofibrate—Hypotension—Carmustine—lymphatic system cancer	0.000791	0.00144	CcSEcCtD
Fenofibrate—Oedema—Mitoxantrone—lymphatic system cancer	0.000787	0.00144	CcSEcCtD
Fenofibrate—Nausea—Fludarabine—lymphatic system cancer	0.000785	0.00143	CcSEcCtD
Fenofibrate—Infection—Mitoxantrone—lymphatic system cancer	0.000781	0.00143	CcSEcCtD
Fenofibrate—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000781	0.00143	CcSEcCtD
Fenofibrate—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000771	0.00141	CcSEcCtD
Fenofibrate—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00077	0.00141	CcSEcCtD
Fenofibrate—Urticaria—Bleomycin—lymphatic system cancer	0.00077	0.00141	CcSEcCtD
Fenofibrate—Anorexia—Vincristine—lymphatic system cancer	0.00077	0.00141	CcSEcCtD
Fenofibrate—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000768	0.0014	CcSEcCtD
Fenofibrate—Body temperature increased—Bleomycin—lymphatic system cancer	0.000766	0.0014	CcSEcCtD
Fenofibrate—Insomnia—Carmustine—lymphatic system cancer	0.000765	0.0014	CcSEcCtD
Fenofibrate—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000764	0.0014	CcSEcCtD
Fenofibrate—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00076	0.00139	CcSEcCtD
Fenofibrate—Paraesthesia—Carmustine—lymphatic system cancer	0.00076	0.00139	CcSEcCtD
Fenofibrate—Hypotension—Vincristine—lymphatic system cancer	0.000755	0.00138	CcSEcCtD
Fenofibrate—Dyspnoea—Carmustine—lymphatic system cancer	0.000754	0.00138	CcSEcCtD
Fenofibrate—Somnolence—Carmustine—lymphatic system cancer	0.000752	0.00137	CcSEcCtD
Fenofibrate—Anorexia—Mitoxantrone—lymphatic system cancer	0.00075	0.00137	CcSEcCtD
Fenofibrate—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000736	0.00134	CcSEcCtD
Fenofibrate—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000736	0.00134	CcSEcCtD
Fenofibrate—Decreased appetite—Carmustine—lymphatic system cancer	0.000736	0.00134	CcSEcCtD
Fenofibrate—Hypotension—Mitoxantrone—lymphatic system cancer	0.000735	0.00134	CcSEcCtD
Fenofibrate—Insomnia—Vincristine—lymphatic system cancer	0.000731	0.00133	CcSEcCtD
Fenofibrate—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00073	0.00133	CcSEcCtD
Fenofibrate—Paraesthesia—Vincristine—lymphatic system cancer	0.000725	0.00132	CcSEcCtD
Fenofibrate—Constipation—Carmustine—lymphatic system cancer	0.000724	0.00132	CcSEcCtD
Fenofibrate—Pain—Carmustine—lymphatic system cancer	0.000724	0.00132	CcSEcCtD
Fenofibrate—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000717	0.00131	CcSEcCtD
Fenofibrate—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000714	0.0013	CcSEcCtD
Fenofibrate—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000706	0.00129	CcSEcCtD
Fenofibrate—Decreased appetite—Vincristine—lymphatic system cancer	0.000702	0.00128	CcSEcCtD
Fenofibrate—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000701	0.00128	CcSEcCtD
Fenofibrate—Somnolence—Mitoxantrone—lymphatic system cancer	0.000699	0.00128	CcSEcCtD
Fenofibrate—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000697	0.00127	CcSEcCtD
Fenofibrate—Feeling abnormal—Carmustine—lymphatic system cancer	0.000697	0.00127	CcSEcCtD
Fenofibrate—Fatigue—Vincristine—lymphatic system cancer	0.000696	0.00127	CcSEcCtD
Fenofibrate—Asthenia—Bleomycin—lymphatic system cancer	0.000695	0.00127	CcSEcCtD
Fenofibrate—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000692	0.00126	CcSEcCtD
Fenofibrate—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000692	0.00126	CcSEcCtD
Fenofibrate—Pain—Vincristine—lymphatic system cancer	0.000691	0.00126	CcSEcCtD
Fenofibrate—Constipation—Vincristine—lymphatic system cancer	0.000691	0.00126	CcSEcCtD
Fenofibrate—Asthma—Methotrexate—lymphatic system cancer	0.000689	0.00126	CcSEcCtD
Fenofibrate—Pruritus—Bleomycin—lymphatic system cancer	0.000686	0.00125	CcSEcCtD
Fenofibrate—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000684	0.00125	CcSEcCtD
Fenofibrate—Eosinophilia—Methotrexate—lymphatic system cancer	0.000682	0.00125	CcSEcCtD
Fenofibrate—Fatigue—Mitoxantrone—lymphatic system cancer	0.000678	0.00124	CcSEcCtD
Fenofibrate—Pancreatitis—Methotrexate—lymphatic system cancer	0.000676	0.00123	CcSEcCtD
Fenofibrate—Pain—Mitoxantrone—lymphatic system cancer	0.000673	0.00123	CcSEcCtD
Fenofibrate—Constipation—Mitoxantrone—lymphatic system cancer	0.000673	0.00123	CcSEcCtD
Fenofibrate—Abdominal pain—Carmustine—lymphatic system cancer	0.000669	0.00122	CcSEcCtD
Fenofibrate—Body temperature increased—Carmustine—lymphatic system cancer	0.000669	0.00122	CcSEcCtD
Fenofibrate—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00066	0.00121	CcSEcCtD
Fenofibrate—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000648	0.00118	CcSEcCtD
Fenofibrate—Dysuria—Methotrexate—lymphatic system cancer	0.000644	0.00118	CcSEcCtD
Fenofibrate—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000643	0.00117	CcSEcCtD
Fenofibrate—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000641	0.00117	CcSEcCtD
Fenofibrate—Body temperature increased—Vincristine—lymphatic system cancer	0.000639	0.00117	CcSEcCtD
Fenofibrate—Abdominal pain—Vincristine—lymphatic system cancer	0.000639	0.00117	CcSEcCtD
Fenofibrate—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000635	0.00116	CcSEcCtD
Fenofibrate—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000629	0.00115	CcSEcCtD
Fenofibrate—Urticaria—Mitoxantrone—lymphatic system cancer	0.000625	0.00114	CcSEcCtD
Fenofibrate—Hypersensitivity—Carmustine—lymphatic system cancer	0.000623	0.00114	CcSEcCtD
Fenofibrate—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000622	0.00114	CcSEcCtD
Fenofibrate—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000622	0.00114	CcSEcCtD
Fenofibrate—Pneumonia—Methotrexate—lymphatic system cancer	0.000618	0.00113	CcSEcCtD
Fenofibrate—Vomiting—Bleomycin—lymphatic system cancer	0.000616	0.00113	CcSEcCtD
Fenofibrate—Infestation NOS—Methotrexate—lymphatic system cancer	0.000614	0.00112	CcSEcCtD
Fenofibrate—Infestation—Methotrexate—lymphatic system cancer	0.000614	0.00112	CcSEcCtD
Fenofibrate—Rash—Bleomycin—lymphatic system cancer	0.000611	0.00112	CcSEcCtD
Fenofibrate—Dermatitis—Bleomycin—lymphatic system cancer	0.000611	0.00112	CcSEcCtD
Fenofibrate—Asthenia—Carmustine—lymphatic system cancer	0.000607	0.00111	CcSEcCtD
Fenofibrate—Renal failure—Methotrexate—lymphatic system cancer	0.000604	0.0011	CcSEcCtD
Fenofibrate—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000597	0.00109	CcSEcCtD
Fenofibrate—Hypersensitivity—Vincristine—lymphatic system cancer	0.000595	0.00109	CcSEcCtD
Fenofibrate—Sweating—Methotrexate—lymphatic system cancer	0.000589	0.00108	CcSEcCtD
Fenofibrate—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000581	0.00106	CcSEcCtD
Fenofibrate—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00058	0.00106	CcSEcCtD
Fenofibrate—Asthenia—Vincristine—lymphatic system cancer	0.00058	0.00106	CcSEcCtD
Fenofibrate—Diarrhoea—Carmustine—lymphatic system cancer	0.000579	0.00106	CcSEcCtD
Fenofibrate—Nausea—Bleomycin—lymphatic system cancer	0.000576	0.00105	CcSEcCtD
Fenofibrate—Asthenia—Mitoxantrone—lymphatic system cancer	0.000564	0.00103	CcSEcCtD
Fenofibrate—Dizziness—Carmustine—lymphatic system cancer	0.00056	0.00102	CcSEcCtD
Fenofibrate—Diarrhoea—Vincristine—lymphatic system cancer	0.000553	0.00101	CcSEcCtD
Fenofibrate—Hepatitis—Methotrexate—lymphatic system cancer	0.000552	0.00101	CcSEcCtD
Fenofibrate—Pharyngitis—Methotrexate—lymphatic system cancer	0.000547	0.001	CcSEcCtD
Fenofibrate—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000538	0.000983	CcSEcCtD
Fenofibrate—Vomiting—Carmustine—lymphatic system cancer	0.000538	0.000982	CcSEcCtD
Fenofibrate—Dizziness—Vincristine—lymphatic system cancer	0.000534	0.000975	CcSEcCtD
Fenofibrate—Rash—Carmustine—lymphatic system cancer	0.000533	0.000974	CcSEcCtD
Fenofibrate—Dermatitis—Carmustine—lymphatic system cancer	0.000533	0.000973	CcSEcCtD
Fenofibrate—Visual impairment—Methotrexate—lymphatic system cancer	0.000532	0.000971	CcSEcCtD
Fenofibrate—Headache—Carmustine—lymphatic system cancer	0.00053	0.000968	CcSEcCtD
Fenofibrate—Eye disorder—Methotrexate—lymphatic system cancer	0.000516	0.000941	CcSEcCtD
Fenofibrate—Vomiting—Vincristine—lymphatic system cancer	0.000514	0.000938	CcSEcCtD
Fenofibrate—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000512	0.000935	CcSEcCtD
Fenofibrate—Rash—Vincristine—lymphatic system cancer	0.000509	0.00093	CcSEcCtD
Fenofibrate—Dermatitis—Vincristine—lymphatic system cancer	0.000509	0.000929	CcSEcCtD
Fenofibrate—Headache—Vincristine—lymphatic system cancer	0.000506	0.000924	CcSEcCtD
Fenofibrate—Nausea—Carmustine—lymphatic system cancer	0.000503	0.000918	CcSEcCtD
Fenofibrate—Angiopathy—Methotrexate—lymphatic system cancer	0.0005	0.000914	CcSEcCtD
Fenofibrate—Vomiting—Mitoxantrone—lymphatic system cancer	0.0005	0.000913	CcSEcCtD
Fenofibrate—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000497	0.000908	CcSEcCtD
Fenofibrate—Rash—Mitoxantrone—lymphatic system cancer	0.000496	0.000906	CcSEcCtD
Fenofibrate—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000496	0.000905	CcSEcCtD
Fenofibrate—Headache—Mitoxantrone—lymphatic system cancer	0.000493	0.0009	CcSEcCtD
Fenofibrate—Alopecia—Methotrexate—lymphatic system cancer	0.000487	0.00089	CcSEcCtD
Fenofibrate—Mental disorder—Methotrexate—lymphatic system cancer	0.000483	0.000883	CcSEcCtD
Fenofibrate—Malnutrition—Methotrexate—lymphatic system cancer	0.00048	0.000877	CcSEcCtD
Fenofibrate—Erythema—Methotrexate—lymphatic system cancer	0.00048	0.000877	CcSEcCtD
Fenofibrate—Nausea—Vincristine—lymphatic system cancer	0.00048	0.000876	CcSEcCtD
Fenofibrate—Nausea—Mitoxantrone—lymphatic system cancer	0.000467	0.000853	CcSEcCtD
Fenofibrate—Back pain—Methotrexate—lymphatic system cancer	0.000465	0.000848	CcSEcCtD
Fenofibrate—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000446	0.000814	CcSEcCtD
Fenofibrate—Anaemia—Methotrexate—lymphatic system cancer	0.000444	0.000811	CcSEcCtD
Fenofibrate—Malaise—Methotrexate—lymphatic system cancer	0.000433	0.000791	CcSEcCtD
Fenofibrate—Vertigo—Methotrexate—lymphatic system cancer	0.000431	0.000788	CcSEcCtD
Fenofibrate—Leukopenia—Methotrexate—lymphatic system cancer	0.00043	0.000785	CcSEcCtD
Fenofibrate—Cough—Methotrexate—lymphatic system cancer	0.000419	0.000765	CcSEcCtD
Fenofibrate—Chest pain—Methotrexate—lymphatic system cancer	0.000409	0.000747	CcSEcCtD
Fenofibrate—Myalgia—Methotrexate—lymphatic system cancer	0.000409	0.000747	CcSEcCtD
Fenofibrate—Arthralgia—Methotrexate—lymphatic system cancer	0.000409	0.000747	CcSEcCtD
Fenofibrate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000406	0.000741	CcSEcCtD
Fenofibrate—Discomfort—Methotrexate—lymphatic system cancer	0.000404	0.000738	CcSEcCtD
Fenofibrate—Infection—Methotrexate—lymphatic system cancer	0.000389	0.000711	CcSEcCtD
Fenofibrate—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000384	0.000702	CcSEcCtD
Fenofibrate—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000384	0.000701	CcSEcCtD
Fenofibrate—Skin disorder—Methotrexate—lymphatic system cancer	0.000381	0.000695	CcSEcCtD
Fenofibrate—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000379	0.000692	CcSEcCtD
Fenofibrate—Anorexia—Methotrexate—lymphatic system cancer	0.000374	0.000682	CcSEcCtD
Fenofibrate—Hypotension—Methotrexate—lymphatic system cancer	0.000366	0.000669	CcSEcCtD
Fenofibrate—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000357	0.000652	CcSEcCtD
Fenofibrate—Insomnia—Methotrexate—lymphatic system cancer	0.000354	0.000647	CcSEcCtD
Fenofibrate—Paraesthesia—Methotrexate—lymphatic system cancer	0.000352	0.000643	CcSEcCtD
Fenofibrate—Dyspnoea—Methotrexate—lymphatic system cancer	0.000349	0.000638	CcSEcCtD
Fenofibrate—Somnolence—Methotrexate—lymphatic system cancer	0.000348	0.000636	CcSEcCtD
Fenofibrate—Dyspepsia—Methotrexate—lymphatic system cancer	0.000345	0.00063	CcSEcCtD
Fenofibrate—Decreased appetite—Methotrexate—lymphatic system cancer	0.000341	0.000622	CcSEcCtD
Fenofibrate—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000338	0.000618	CcSEcCtD
Fenofibrate—Fatigue—Methotrexate—lymphatic system cancer	0.000338	0.000617	CcSEcCtD
Fenofibrate—Pain—Methotrexate—lymphatic system cancer	0.000335	0.000612	CcSEcCtD
Fenofibrate—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000323	0.00059	CcSEcCtD
Fenofibrate—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00032	0.000585	CcSEcCtD
Fenofibrate—Urticaria—Methotrexate—lymphatic system cancer	0.000311	0.000569	CcSEcCtD
Fenofibrate—Abdominal pain—Methotrexate—lymphatic system cancer	0.00031	0.000566	CcSEcCtD
Fenofibrate—Body temperature increased—Methotrexate—lymphatic system cancer	0.00031	0.000566	CcSEcCtD
Fenofibrate—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000289	0.000527	CcSEcCtD
Fenofibrate—Asthenia—Methotrexate—lymphatic system cancer	0.000281	0.000514	CcSEcCtD
Fenofibrate—Pruritus—Methotrexate—lymphatic system cancer	0.000277	0.000506	CcSEcCtD
Fenofibrate—Diarrhoea—Methotrexate—lymphatic system cancer	0.000268	0.00049	CcSEcCtD
Fenofibrate—Dizziness—Methotrexate—lymphatic system cancer	0.000259	0.000473	CcSEcCtD
Fenofibrate—Vomiting—Methotrexate—lymphatic system cancer	0.000249	0.000455	CcSEcCtD
Fenofibrate—Rash—Methotrexate—lymphatic system cancer	0.000247	0.000451	CcSEcCtD
Fenofibrate—Dermatitis—Methotrexate—lymphatic system cancer	0.000247	0.000451	CcSEcCtD
Fenofibrate—Headache—Methotrexate—lymphatic system cancer	0.000246	0.000448	CcSEcCtD
Fenofibrate—Nausea—Methotrexate—lymphatic system cancer	0.000233	0.000425	CcSEcCtD
